CN113293130A - Culture method of tumor specific T cells - Google Patents
Culture method of tumor specific T cells Download PDFInfo
- Publication number
- CN113293130A CN113293130A CN202010800226.5A CN202010800226A CN113293130A CN 113293130 A CN113293130 A CN 113293130A CN 202010800226 A CN202010800226 A CN 202010800226A CN 113293130 A CN113293130 A CN 113293130A
- Authority
- CN
- China
- Prior art keywords
- cells
- culture medium
- tumor
- specific
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 66
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 64
- 238000012136 culture method Methods 0.000 title abstract description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 80
- 239000001963 growth medium Substances 0.000 claims abstract description 44
- 239000001103 potassium chloride Substances 0.000 claims abstract description 39
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000012258 culturing Methods 0.000 claims abstract description 8
- 210000005087 mononuclear cell Anatomy 0.000 claims description 20
- 210000005259 peripheral blood Anatomy 0.000 claims description 18
- 239000011886 peripheral blood Substances 0.000 claims description 18
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 16
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 16
- 239000002609 medium Substances 0.000 claims description 13
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 7
- 239000006143 cell culture medium Substances 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 108010067306 Fibronectins Proteins 0.000 claims description 6
- 102000016359 Fibronectins Human genes 0.000 claims description 6
- 229920001917 Ficoll Polymers 0.000 claims description 6
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 230000001745 anti-biotin effect Effects 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 238000007885 magnetic separation Methods 0.000 claims description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 3
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 claims description 3
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 claims description 3
- 229940024606 amino acid Drugs 0.000 claims description 3
- 102000056003 human IL15 Human genes 0.000 claims description 3
- 102000052622 human IL7 Human genes 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940031098 ethanolamine Drugs 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 229960002337 magnesium chloride Drugs 0.000 claims description 2
- -1 nicotinamide, amino acids Chemical class 0.000 claims description 2
- 239000004017 serum-free culture medium Substances 0.000 claims description 2
- 229960002668 sodium chloride Drugs 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 229940054269 sodium pyruvate Drugs 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 44
- 230000000694 effects Effects 0.000 abstract description 13
- 210000003071 memory t lymphocyte Anatomy 0.000 abstract description 11
- 238000009169 immunotherapy Methods 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 17
- 238000004113 cell culture Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000012467 final product Substances 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 238000011282 treatment Methods 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 2
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a culture medium for culturing tumor-specific T cells, which comprises potassium chloride with the concentration of more than 1g/L and less than or equal to 4g/L, preferably X-VIVO culture medium, GT-T551 culture medium and ALYS505N-0 culture medium containing 3g/L potassium chloride. Based on the culture medium, the invention also provides a culture method of the tumor specific T cells, and potassium chloride with the concentration of more than 1g/L and less than or equal to 4g/L is added into the culture medium in the culture process. The cell product cultured by the culture medium and the culture method provided by the invention has higher proportion of tumor specific cells and improved proportion of memory T cells, and is suitable for being applied to clinically improving the adoptive immunotherapy effect.
Description
Technical Field
The invention belongs to the technical field of cell culture, and particularly relates to a culture method of tumor specific T cells.
Background
Malignant tumor is a common disease seriously harming human life health, and the treatment method of the malignant tumor mainly comprises surgical treatment, chemical treatment, radiation treatment and the like. However, the above-mentioned treatments have very limited therapeutic effects, and biological therapies mainly directed to immunology are increasingly advantageous, in which tumor-specific T lymphocytes (CTL) play an important role in the course of anti-tumor immunity.
The tumor specific T lymphocyte is a subgroup of T cells, and CTL is proliferated and differentiated under the premise of antigen stimulation and the assistance of cytokines to be activated into the T cells with specific killing activity. CTL is the main medium of the adoptive immunotherapy of the tumor, the adoptive immunotherapy is to direct the tumor patient to transfuse immune cells with anti-tumor activity, and directly kill the tumor or stimulate the immune response of the organism to kill the tumor cells, thereby achieving the purpose of treating the tumor.
One of the keys of the adoptive immunotherapy using CTL is to try to obtain a large amount of CTL in vitro, i.e. to screen effector cells with tumor-specific killing effect, so as to realize the features of high efficiency and low toxicity of adoptive immunotherapy. The T cell with tumor antigen specificity has the characteristics of wide tumor killing spectrum, high tumor killing activity, strong proliferation capacity and the like. How to increase the number and activity of CTL cells in vitro culture products and enhance the anti-tumor specificity of the CTL cells is the key point for improving the effect of adoptive immunotherapy.
Current research on specific T cell culture methods has focused mainly on the induction mode.
Chinese patent 201910420697.0 discloses a method for isolating and culturing tumor-specific T cells, which comprises using peripheral blood of a tumor patient as a material, adding a PD-1 antibody to the peripheral blood, incubating, isolating mononuclear cells, and inoculating into a culture flask coated with a recombinant human fibronectin fragment and an anti-human CD3 activating antibody. The method has the advantages of easily-accessible raw materials, and high tumor specificity of the obtained T cells, and contains both CD 4-positive and CD 8-positive T cells. However, the final product obtained by the method has a low proportion of effector memory T cells contained by CD4 positive cells and CD8 positive cells, and has a further optimization space.
Chinese patent 200510038728.4 discloses an in vitro amplification method of tumor antigen specific T lymphocytes, which involves the combined use of interleukin 2, interleukin 15, an excitatory anti-CD 28 monoclonal antibody and tumor antigen loaded antigen presenting cells to induce T cells to become cytotoxic T lymphocytes.
The effect of the specific T cell medium composition on the culture effect is still under extensive study.
Chinese patent 201810955224.6 discloses an immune cell culture medium and its application, which explores the influence of various inorganic salts such as anhydrous calcium chloride, various amino acids such as L-leucine, interleukin 2, interleukin 4 and other components on immune cell culture. However, the culture medium provided by the invention has complicated and variable component types and large component concentration range, and the specific component concentration of the culture medium with the optimal culture effect cannot be determined, thereby bringing great difficulty in culture selection.
The general concentration of potassium chloride in a culture medium of general specific T cells or immune cells is lower (Chinese patent 201810955224.6: 310.5 mg/L-311.3 mg/L; Chinese patent 201711319524.7: 10-1000 mg/L; Chinese patent 201711321217.2: 10-1000 mg/L; Chinese patent 201710797665.3: 250-500mg/L), the highest concentration of potassium chloride conventionally used in the field is 1g/L, and the proportion of total specific T cells and memory T cells of a final product of cell culture is improved by optimizing the concentration of potassium chloride in the culture medium.
Disclosure of Invention
The invention provides a culture medium and a culture method for culturing tumor-specific T cells. The content of potassium chloride in the conventional tumor specific T cells is up to 1g/L, and the invention unexpectedly discovers that the proportion of the tumor specific T cells is higher and the proportion of the memory T cells is also improved in cell products cultured by a culture medium containing high-concentration potassium chloride.
In one aspect, the invention provides a culture medium for tumor-specific T cell culture.
The concentration of potassium chloride in the culture medium is more than 1g/L and less than or equal to 4 g/L.
Preferably, the culture medium comprises potassium chloride with the concentration of 3 g/L.
The culture medium includes but is not limited to serum-free culture medium; the culture medium includes but is not limited to KBM581 culture medium, GT-T551 culture medium, X-VIVO culture medium, GT-T505 culture medium, StemXVivo culture medium, TexMACS GMP culture medium, EX-CELL culture medium, ImmunoCult culture medium, ALYS505N-0 culture medium.
The components of the culture medium include but are not limited to: anhydrous calcium chloride, lipoic acid, sodium pyruvate, magnesium chloride, vitamins, ethanolamine, sodium chloride, nicotinamide, amino acids and antibiotics.
In some embodiments, the medium is X-VIVO medium supplemented with 3g/L potassium chloride.
In some embodiments, the medium is GT-T551 medium supplemented with 3g/L potassium chloride.
In some embodiments, the medium is ALYS505N-0 supplemented with 3g/L potassium chloride.
Optionally, the culture medium further comprises one or more of human IL-2, human IL-7, human IL-15 or human IL-21, preferably at a final concentration of 0.1X 106-7×106U/L human IL-2.
In another aspect, the invention provides a method of culturing tumor-specific T cells.
The culture method comprises the following steps:
(1) peripheral blood PD-1 pretreatment of tumor patients;
(2) obtaining mononuclear cells from the peripheral blood in the step (1) by adopting a Ficoll density gradient method;
(3) incubating the mononuclear cells separated in the step (2) with biotinylated anti-human IgG4 antibody at 25 ℃ for 20min, adding magnetic beads coated with anti-biotin antibody, incubating at 25 ℃ for 20min, and performing magnetic separation to obtain PD-1 positive mononuclear cells;
(4) and (3) resuspending the PD-1 positive mononuclear cells separated in the step (3) by using a serum-free culture solution, wherein the serum-free culture solution comprises potassium chloride with the concentration of more than 1g/L and less than or equal to 4g/L, and performing amplification culture on the resuspended mononuclear cells to obtain a product of the tumor specific T cells.
The tumor patient in the step (1) is one of lung cancer, kidney cancer, intestinal cancer, esophageal cancer, malignant melanoma or cholangiocarcinoma patients.
The pretreatment method in the step (1) is to add the PD-1 antibody into peripheral blood after a tumor patient receives the PD-1 antibody treatment or takes out the peripheral blood of the tumor patient, and then incubate.
Further, in the step (1), after peripheral blood of a tumor patient is taken out during pretreatment, PD-1 antibody is added into the peripheral blood to achieve the final concentration of 0.2-0.8 mu g/mL, the incubation temperature is 0-6 ℃, and the incubation time is 0.5-24 h.
The addition amount of potassium chloride in the serum-free culture solution in the step (4) is preferably 3 g/L.
The serum-free culture solution in the step (4) also comprises one or more of human IL-2, human IL-7, human IL-15 or human IL-21, and the final concentration is preferably 0.1X 106-7×106U/L human IL-2.
The amplification culture method in the step (4) is to seed the strain into a pre-coated bottle, the pre-coated bottle is treated by fibronectin, and the pre-coated bottle is also treated by anti-human CD3 antibody or OKT 3; wherein the concentration of fibronectin is 0.5-10 μ g/mL, preferably 6 μ g/mL; the concentration of the anti-human CD3 antibody is 0.1-4 mug/mL, preferably 1.5 mug/mL; the number of days of culture is 8 to 15 days, preferably 10 days.
In yet another aspect, the invention also provides a product comprising tumor specific T cells.
The product contains the tumor specific T cell final product obtained by the culture method.
The product types include, but are not limited to, pharmaceuticals and vaccines.
Compared with the culture method of specific T cells disclosed at present, the final cell product of the culture method provided by the invention has higher proportion of tumor specific cells, and the proportion of memory T cells is also improved.
Drawings
FIG. 1 shows that the specific T cell culture end product in the presence of high concentration of potassium chloride stimulates the secretion of IFN-. gamma.cells occupying CD8 in tumor cells derived from tumor patients (not treated with anti-PD-1 antibody)+And CD4+The proportion of cells.
FIG. 2 shows the secretion of IFN-. gamma.cells occupying CD8 by specific T cell culture final product in the presence of high concentration of potassium chloride under stimulation by tumor cells derived from tumor patients (treated with anti-PD-1 antibody)+And CD4+The proportion of cells.
FIG. 3 shows the ratio of effective memory T cells in the final product of specific T cell culture (L-TIL cell product) under high concentration of potassium chloride.
FIG. 4 is a graph showing the proportion of potent memory T cells in the final product of specific T cell culture (CD19-CART cell product) under high potassium chloride concentration conditions.
Detailed Description
The present invention will be further illustrated in detail with reference to the following specific examples, which are not intended to limit the present invention but are merely illustrative thereof. The experimental methods used in the following examples are not specifically described, and the materials, reagents and the like used in the following examples are generally commercially available under the usual conditions without specific descriptions.
EXAMPLE 1 Effect of high concentrations of Potassium chloride on the proportion of (tumor) antigen-specific T cells in the final product of a specific T cell culture (patients not receiving anti-PD-1 antibody treatment)
(1) Taking peripheral blood of a malignant melanoma patient, adding a PD-1 antibody for incubation (pretreatment);
(2) obtaining mononuclear cells from the peripheral blood in the step (1) by adopting a Ficoll density gradient method;
(3) and (3) incubating the mononuclear cells obtained in the step (2) with biotinylated anti-human IgG4 antibody for 20min at 25 ℃, adding magnetic beads coated with anti-biotin antibody for incubating for 20min at 25 ℃, and performing magnetic separation to obtain the mononuclear cells positive to PD-1.
(4) Respectively resuspending the cells in the step (3) by using potassium chloride-added serum-free culture solution (the serum-free culture solution is purchased from semer fly) with the concentration of 3g/L and serum-free culture solution without potassium chloride, respectively inoculating 6 mu g/mL fibronectin and 1.5 mu g/mL anti-human CD3 antibody into the resuspended mononuclear cells, then respectively carrying out amplification on the mononuclear cells in a pre-coated culture flask, obtaining the amplified T cells after 14 days, and counting the CD8 occupation of IFN-gamma cells secreted by the IFN-gamma cells under the stimulation of tumor cells+And CD4+The proportion of cells. The specific method comprises the following steps:
obtaining autologous tumor cells (derived from tumor tissue) of a tumor patient: cutting the tumor tissue obtained by operation, adding collagenase, hyaluronidase and DNase, digesting for 0.5-2h in a constant temperature incubator at 37 ℃, and then washing for 2 times by using phosphate buffer solution. Tumor cells were obtained by Ficoll density gradient method and frozen in liquid nitrogen (as target cells for specific T lymphocytes).
Specific T lymphocyte evaluation (co-incubation method): taking the two groups of cultured T cells (a potassium chloride group with the concentration of 3g/L and a potassium chloride-free group), washing for two times by serum-free culture solution, then re-suspending by the serum-free culture solution which is added with IFN-gamma secretion blocker Brefeldin A (the concentration is 5ng/mL) and does not contain any cell factor, mixing with autologous tumor cells according to the proportion of 1:1, and incubating in a constant-temperature incubator at 37 ℃ for 6h and then collecting the cells. Marking CD3, CD4 and CD8 fluorescent antibodies on the cell surface, adding a fixing solution for fixation, breaking membranes by using an intracellular staining kit, marking IFN-gamma fluorescent antibodies, and detecting whether IFN-gamma cells secreting the cells account for CD8 by using a flow cytometer+And CD4+Proportion of cells (CD8+ IFN-. gamma.)+%,CD4+IFN-γ+%)。
The results of the relevant experiments are shown in FIG. 1, which shows that the specific T cell ratio of the tumor antigen in the final product of the specific T cell cultured by adding the culture medium with high concentration (3g/L) of potassium chloride is higher.
EXAMPLE 2 Effect of high concentrations of Potassium chloride on the proportion of (tumor) antigen-specific T cells in the final product of a specific T cell culture (patients treated with anti-PD-1 antibody)
(1) Taking peripheral blood of a patient with malignant melanoma;
(2) obtaining mononuclear cells from the peripheral blood in the step (1) by adopting a Ficoll density gradient method;
(3) and (3) incubating the mononuclear cells obtained in the step (2) with biotinylated anti-human IgG4 antibody for 20min at 25 ℃, adding magnetic beads coated with anti-biotin antibody for incubating for 20min at 25 ℃, and performing magnetic separation to obtain the mononuclear cells positive to PD-1.
(4) The cells in the step (3) are respectively resuspended by potassium chloride-added serum-free culture solution (serum-free culture solution is purchased from Saimer fly) and potassium chloride-free serum-free culture solution, the resuspended mononuclear cells are respectively inoculated with 6 mu g/mL fibronectin and 1.5 mu g/mL anti-human CD3 antibody-treated pre-coated culture bottles for amplification, after 14 days, the amplified T cells are obtained, and the tumor cells are subjected to cell cultureThe CD8 of IFN-gamma cell is counted under stimulation+And CD4+The proportion of cells. The specific method comprises the following steps:
obtaining autologous tumor cells (derived from tumor tissue) of a tumor patient: cutting the tumor tissue obtained by operation, adding collagenase, hyaluronidase and DNase, digesting for 0.5-2h in a constant temperature incubator at 37 ℃, and then washing for 2 times by using phosphate buffer solution. Tumor cells were obtained by Ficoll density gradient method and frozen in liquid nitrogen (as target cells for specific T lymphocytes).
Specific T lymphocyte evaluation (co-incubation method): taking the two groups of cultured T cells (a potassium chloride group with the concentration of 3g/L and a potassium chloride-free group), washing for two times by serum-free culture solution, then re-suspending by the serum-free culture solution which is added with IFN-gamma secretion blocker Brefeldin A (the concentration is 5ng/mL) and does not contain any cell factor, mixing with autologous tumor cells according to the proportion of 1:1, and incubating in a constant-temperature incubator at 37 ℃ for 6h and then collecting the cells. Marking CD3, CD4 and CD8 fluorescent antibodies on the cell surface, adding a fixing solution for fixation, breaking membranes by using an intracellular staining kit, marking IFN-gamma fluorescent antibodies, and detecting whether IFN-gamma cells secreting the cells account for CD8 by using a flow cytometer+And CD4+Proportion of cells (CD8+ IFN-. gamma.)+%,CD4+IFN-γ+%)。
The results of the relevant experiments are shown in FIG. 2, which shows that the specific T cell ratio of the tumor antigen in the final product of the specific T cell cultured by the medium with high concentration (3g/L) of potassium chloride is higher.
EXAMPLE 3 Effect of high Potassium chloride concentrations on the proportion of effective memory T cells in the final tumor-specific T cell culture product (L-TIL cell product)
(1) Peripheral blood was taken from cancer patients treated with the PD-1 antibody within 3 weeks, 10 patients were involved in the present example, and tumor types and number of patients were as follows: 2 patients with renal cancer, 2 patients with malignant melanoma, 1 patient with lung cancer, 2 patients with liver cancer, 1 patient with stomach cancer, 1 patient with esophageal cancer and 1 patient with intestinal cancer. The tumor patients are selected from tumor hospitals in Henan province and have obtained patient permission.
The procedure of reference example 2 was followed to examine the effect of high concentrations of potassium chloride on the proportion of effector memory T cells in the final tumor-specific T cell culture product.
For effector memory T cell CD3 contained in final product+CD4+CCR7-CD45RA-(CD4+),CD3+CD8+CCR7-CD45RA-(CD8+) The results are shown in FIG. 3. The result shows that the high concentration of potassium chloride (3g/L) can obviously improve the expansion effect of the T cells, and has statistical difference.
Example 4 Effect of high Potassium chloride concentrations on the proportion of potent memory T cells in the final product of specific T cell cultures (CD19-CART cell product)
CD19-CART cells were cultured in a medium containing 3g/L potassium chloride (LONZA, X-VIVO medium) and a medium containing no potassium chloride (LONZA, X-VIVO medium), and 4 groups of parallel CD19-CART cells were prepared and cultured in reference to 201810462786.7 (paragraph 0050-0062), which is a difference between the two media.
After the culture is finished, detecting a CD19-CART cell product, wherein the specific detection method comprises the following steps: the collected cells were washed 2 times with PBS and their expression of surface markers CD4, CD8, CD45RA, CCR7 and CD19CAR was detected by flow cytometry.
The results are shown in FIG. 4, the ratio of the T cells with memory effect in the final product of T cells cultured in the medium containing high concentration (3g/L) of potassium chloride is obviously increased, which indicates that the high concentration of potassium chloride can improve the expansion effect of T cells.
Comparative example 1
Compared with the method disclosed in the Chinese patent 201910420697.0, the method disclosed by the application is adopted to carry out a comparison experiment, only the concentration of potassium chloride in the culture medium is different in the experimental setting, and peripheral blood is taken from a renal cancer patient treated by PD-1 in the comparison experiment. The results are as follows:
it should be noted that: 3g/L of potassium chloride in the culture medium is added with KCl with the final concentration of 3g/L on the basis of the original commercial culture solution, so that when the culture medium is compared with the original commercial culture medium, the relative potassium chloride content of the comparative example is 0 g/L.
Claims (10)
1. A tumor-specific T cell culture medium, wherein the concentration of potassium chloride in the culture medium is greater than 1g/L and less than or equal to 4 g/L.
2. The tumor specific T cell culture medium of claim 1, wherein the medium comprises potassium chloride at a concentration of 3 g/L.
3. The tumor specific T cell culture medium of claim 1, wherein the culture medium is a serum-free medium; the culture medium is one of KBM581 culture medium, GT-T551 culture medium, X-VIVO culture medium, GT-T505 culture medium, StemXVivo culture medium, TexMACS GMP culture medium, EX-CELL culture medium, ImmunoCult culture medium or ALYS505N-0 culture medium.
4. The tumor specific T cell culture medium of any one of claims 1-3, further comprising one or more of anhydrous calcium chloride, lipoic acid, sodium pyruvate, magnesium chloride, vitamins, ethanolamine, sodium chloride, nicotinamide, amino acids, and antibiotics.
5. A method of culturing tumor-specific T cells, comprising the steps of:
(1) peripheral blood PD-1 pretreatment of tumor patients;
(2) obtaining mononuclear cells from the peripheral blood in the step (1) by adopting a Ficoll density gradient method;
(3) incubating the mononuclear cells separated in the step (2) with biotinylated anti-human IgG4 antibody at 25 ℃ for 20min, adding magnetic beads coated with anti-biotin antibody, incubating at 25 ℃ for 20min, and performing magnetic separation to obtain PD-1 positive mononuclear cells;
(4) and (3) resuspending the PD-1 positive mononuclear cells separated in the step (3) by using a serum-free culture solution, wherein the serum-free culture solution comprises potassium chloride with the concentration of more than 1g/L and less than or equal to 4g/L, and performing amplification culture on the resuspended mononuclear cells to obtain a product of the tumor specific T cells.
6. The method for culturing T cells specific to tumor according to claim 5, wherein the amplification culture in step (4) is performed by seeding into pre-coated flasks, the pre-coated flasks are treated with fibronectin, and the pre-coated flasks are further treated with anti-human CD3 antibody or OKT 3; wherein the concentration of fibronectin is 0.5-10 μ g/mL; the concentration of the anti-human CD3 antibody is 0.1-4 mug/mL; the culture days are 8-15 days.
7. The method of claim 5, wherein the serum-free culture medium of step (4) further comprises one or more of human IL-2, human IL-7, human IL-15, or human IL-21.
8. The method for culturing T cells specific to tumor according to claim 7, wherein the serum-free culture solution in step (4) further comprises a final concentration of 0.1X 106-7×106U/L human IL-2.
9. The method for culturing T cells specific to tumor according to claim 8, wherein the PD-1 antibody is added to peripheral blood of the tumor patient at a final concentration of 0.2-0.8 μ g/mL after the peripheral blood is removed during the pretreatment in step (1), the temperature of the incubation is 0-6 ℃, and the incubation time is 0.5-24 h.
10. A product containing tumor-specific T cells, comprising the tumor-specific T cells produced by the method of any one of claims 5 to 9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010800226.5A CN113293130B (en) | 2020-08-11 | 2020-08-11 | Culture method of tumor specific T cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010800226.5A CN113293130B (en) | 2020-08-11 | 2020-08-11 | Culture method of tumor specific T cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113293130A true CN113293130A (en) | 2021-08-24 |
CN113293130B CN113293130B (en) | 2022-07-12 |
Family
ID=77318163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010800226.5A Active CN113293130B (en) | 2020-08-11 | 2020-08-11 | Culture method of tumor specific T cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113293130B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111961648A (en) * | 2019-05-20 | 2020-11-20 | 河南省肿瘤医院 | Isolated culture method of tumor specific T cells and product obtained by same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110452870A (en) * | 2019-05-20 | 2019-11-15 | 河南省肿瘤医院 | A kind of isolated culture method of tumor specific T cells and the product obtained by it |
CN110592016A (en) * | 2019-10-28 | 2019-12-20 | 上海科医联创生物科技有限公司 | Culture method of specific T cells |
CN110628717A (en) * | 2019-10-28 | 2019-12-31 | 上海科医联创生物科技有限公司 | Method for culturing infiltrating T cells |
CN110760481A (en) * | 2019-10-30 | 2020-02-07 | 武汉科技大学 | Improved RPMI1640 culture medium and application thereof |
CN111440773A (en) * | 2020-04-07 | 2020-07-24 | 上海交通大学 | Optimized culture method for T cell in-vitro chimeric antigen receptor modification and amplification |
-
2020
- 2020-08-11 CN CN202010800226.5A patent/CN113293130B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110452870A (en) * | 2019-05-20 | 2019-11-15 | 河南省肿瘤医院 | A kind of isolated culture method of tumor specific T cells and the product obtained by it |
CN110592016A (en) * | 2019-10-28 | 2019-12-20 | 上海科医联创生物科技有限公司 | Culture method of specific T cells |
CN110628717A (en) * | 2019-10-28 | 2019-12-31 | 上海科医联创生物科技有限公司 | Method for culturing infiltrating T cells |
CN110760481A (en) * | 2019-10-30 | 2020-02-07 | 武汉科技大学 | Improved RPMI1640 culture medium and application thereof |
CN111440773A (en) * | 2020-04-07 | 2020-07-24 | 上海交通大学 | Optimized culture method for T cell in-vitro chimeric antigen receptor modification and amplification |
Non-Patent Citations (1)
Title |
---|
SUMAN KUMAR VODNALA 等: "T cell stemness and dysfunction in tumors are triggered by a common mechanism", 《SCIENCE》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111961648A (en) * | 2019-05-20 | 2020-11-20 | 河南省肿瘤医院 | Isolated culture method of tumor specific T cells and product obtained by same |
CN111961648B (en) * | 2019-05-20 | 2022-03-29 | 河南省肿瘤医院 | Isolated culture method of tumor specific T cells and product obtained by same |
Also Published As
Publication number | Publication date |
---|---|
CN113293130B (en) | 2022-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111961648B (en) | Isolated culture method of tumor specific T cells and product obtained by same | |
Klapper et al. | Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy | |
CN108588022B (en) | Method for enriching human CD4+ and CD8+ TCM cells through in vitro culture | |
CN112877288B (en) | NK cell culture system and application | |
CN102321581B (en) | Preparation method of ascites tumor cell sensitized DC-CIK | |
CN111690610A (en) | Method for preparing natural killer NK (natural killer) cells through efficient induction culture | |
CN109913412B (en) | In vitro induction and/or amplification of TSCMCompositions, media and methods of | |
CN104815323B (en) | A kind of dendritic cell tumor vaccine and preparation method thereof | |
CN106566806A (en) | Method for in-vitro culture and enrichment of CD8+ T cells | |
CN115558641A (en) | High-purity effector immune cell population, and culture method, reagent composition and application thereof | |
CN105969731B (en) | A method of High Fragmentation activity til cell is largely prepared using pernicious Pleural effusions | |
CN105524884A (en) | Preparation method of HLA-A0201 restriction AFP antigen specific CTL | |
CN112662625B (en) | T cell culture medium and method for expanding and culturing T cells by using same | |
CN113293130B (en) | Culture method of tumor specific T cells | |
EP3936611A1 (en) | Composition, culture medium and method for inducing and/or amplifying tscm in vitro | |
CN106701680A (en) | Combination factor for promoting maturity of dendritic cells and method for cultivating dendritic cells | |
CN113943704B (en) | Preparation method of tumor neoantigen specific T cells | |
CN108486055A (en) | Culture medium and its application in central memory-type T lymphocyte cultures | |
CN109666638A (en) | Peripheral blood mononuclear cells is induced into the reagent and its composition therefor for CIK | |
CN113025571B (en) | Treatment method of human peripheral blood T lymphocytes, immunogen preparation and application | |
CN112300992B (en) | NK cell culture solution and multistage activated NK cell culture method | |
CN111690607B (en) | Efficient killer cell in-vitro culture kit and culture method | |
CN105505873A (en) | Preparation method of HLA-A0201 restriction anti-Her2-neu antigen-specific CTL (cytotoxic lymphocyte) | |
CN113881629A (en) | Culture medium and culture method for efficiently amplifying NK cells in vitro | |
CN110564684A (en) | Method for in vitro stabilizing, large-amount amplification and high-cytotoxic-activity NK cells and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240205 Address after: 453000 torch Park, 1789 High-tech Zone, Xinfei Avenue, Xinxiang, Henan Patentee after: HENAN HUALONG BIOTECHNOLOGY Co.,Ltd. Country or region after: China Address before: Department of immunotherapy, Henan Cancer Hospital, 127 Dongming Road, Jinshui District, Zhengzhou City, Henan Province, 450008 Patentee before: HENAN CANCER Hospital Country or region before: China |
|
TR01 | Transfer of patent right |